Tirzepatide

Tirzepatide is a synthetic peptide classified as a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. It is FDA-approved but not classified as a Category 2 substance, meaning it is not currently banned from compounding. Its regulatory status is currently unregulated, and it achieves a trust score of 67.5/100 (Grade B-) on this platform. This score reflects a high research score (90.0) offset by a lower safety score (45.0).

Tirzepatide functions by mimicking the actions of both GLP-1 and GIP, incretin hormones that play a role in glucose regulation and appetite control. GLP-1 receptor activation stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying, leading to improved glycemic control and reduced appetite. GIP receptor activation also stimulates insulin secretion and may have additional effects on energy expenditure and fat metabolism. This dual mechanism of action is believed to contribute to its efficacy in weight loss and management of type 2 diabetes.

The current research landscape surrounding tirzepatide is extensive, with 87 clinical trials and 1893 research papers available. Several large-scale clinical trials are investigating its effects on cardiovascular outcomes. The INTERCEPT-ASCVD trial, sponsored by Brigham and Women's Hospital (n=60000), is designed to assess the impact of incretin-based therapies on cardiovascular event prevention in patients with and without atherosclerotic cardiovascular disease (ASCVD). The TIRZSITA-CVOT trial, also sponsored by Brigham and Women's Hospital (n=49065), compared the cardiovascular effects of tirzepatide versus sitagliptin in individuals at cardiovascular risk. These trials are crucial for understanding the long-term cardiovascular safety and efficacy of tirzepatide. Furthermore, real-world studies, such as the one sponsored by Radboud University Medical Center (n=1700), are examining the effectiveness and dosing patterns of tirzepatide in people with obesity.

The safety profile of tirzepatide is an area of ongoing evaluation. While clinical trials have demonstrated its efficacy, post-market surveillance data, including 120921 reports to the FDA, reveal potential adverse events. Although none of these reports were classified as serious, the most common reactions include incorrect dose administered, injection site pain, nausea, extra dose administered, and off-label use. It is also important to note that tirzepatide carries an FDA black box warning, indicating a potential risk of thyroid C-cell tumors. Research papers have also highlighted potential adverse events, including a real-world pharmacovigilance analysis that examined cardiovascular adverse event reporting profiles, focusing on heart failure, arrhythmias, and ischemic events. Additionally, a case report documented a rare complication of tirzepatide-induced liver injury.

Tirzepatide is commonly used for weight loss, hormonal health, and body composition improvements. Individuals seeking to manage their weight or improve their metabolic health may consider tirzepatide. However, it is essential to note that the peptide is FDA-approved for specific indications, and off-label use is prevalent, as indicated by the FDA adverse event data.

The ongoing research and regulatory scrutiny surrounding tirzepatide suggest a dynamic landscape, with future studies likely to further refine its safety profile and optimal use cases.